About Us
The "World Association of Radiopharmaceutical and Molecular Therapy" (WARMTH) extends its activities throughout the world. WARMTH is the only worldwide organization founded to promote the use of radionuclide molecular therapy, and of the relatively novel paradigm of ‘Theragnostics.’
WARMTH is a voluntary non-profit organization of individuals specifically associated for the purposes, and for using the means, to achieve the following research and educational objectives:
- Advance science and education of therapeutic nuclear medicine and radiopharmaceutical therapy including dosimetry, treatment evaluation, radiation physics, radiation biology and radiation protection for the benefit of public health and humanity.
- Work towards worldwide access to radionuclide therapy by harmonizing good practice.
- Educating nuclear medicine professionals in the use of radionuclide therapies and to facilitate research in this area.Read more: About Us
16th ICRT
The 16th ICRT 2021 is virtual.
December 4-5, 2022
Abstract Submission Closed
Registration Open
All WARMTH Members are automatically registered
On behalf of the 16th ICRT Chair, it is a great pleasure to welcome you to the 16th International Conference on Radiopharmaceutical Therapy (ICRT) of WARMTH virtually.
The two-day conference will bring together the leaders, physicians, scientists, healthcare professionals, and others interested in the challenges related to nuclear medicine and molecular imaging. We assure you of the highest level of scientific discussions relevant to research and policymaking for the promotion of radiopharmaceutical therapy.
Two days - 17 speakers from around the globe.
While we wish we were coming together in person, we look forward to meeting you again virtually with the hope of meeting in person during 2022
Important dates:
Abstracts Close November 9, 2021
Virtual Education Sessions: December 4-5, 2021
Prof. Dr. Partha S. Choudhury 16th ICRT Chair and WARMTH President
Click to download the agenda or click on read more.
World Theragnostics Day
On March 31st we celebrate World “Theragnostics Day” celebrating the day in 1941 when the first radioiodine treatment was administered by Dr. Saul Hertz at Massachusetts General Hospital. The WJNM reflects on this historic first treatment and the continuing innovations in the field of Theragnostics. WARMTH celebrates Theragnotstics Day with a “g” as an article by our colleagues in the EJNMMI points out "“theragnostics” is the better term with its emphasis on knowledge” Frangos, S. & Buscombe, J.R. Eur J Nucl Med Mol Imaging (2019) 46: 519. https://doi.org/10.1007/s00259-018-4204-z
To download a high-resolution PDF for printing click here.
President's Letter End of Year 2020
Dear friends of WARMTH,
It is time to say good-bye to a difficult year going by and we all sincerely hope that the coming year brings to us a safe world to live and work in with our families and friends.
The year 2020 saw us going through difficult times and we all tried to find solutions in different unique ways to survive and keep us healthy and safe from the ongoing pandemic which we guess is the worst ever year as experienced by any of us in our lifetime. Thankfully things appear to be under control in most of the countries and all of us are gradually limping back towards normalcy. The current news of the mutated new deadly strain of the COVID 19 has dampened our year-end spirits a bit but let us hope it is like a passing dark piece of cloud that should go away soon. Once again heartfelt condolences on behalf of WARMTH for those WARMTH members who have passed recently.
COVID-19 and Nuclear Medicine Therapy
The world is going through difficult times and we are all trying to find solutions in different unique ways to keep us and our families safe. “Break the chain” has been a common slogan for all the countries which we can achieve by physical distancing and therefore most of the countries are in complete lockdown. I believe at this point in time we are gradually moving towards the peak of the corona crisis and thinking about the post-pandemic life expected in the next few months.
Videos from the 15th ICRT
ICRT 2020 was held virtually on December 5th and 6th, 2020. To view the online agenda click here.
WARMTH is grateful to the following sponsor who made the 15th ICRT a reality.
WARMTH 617 Study in Print
Ahmadzadehfar, H., Rahbar, K., Baum, R.P. et al. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu]Lu-PSMA-617. A WARMTH multicenter study (the 617 trial). Eur J Nucl Med Mol Imaging (2020). https://doi.org/10.1007/s00259-020-04797-9
WARMTH demonstrated in a multicenter study the impact of prior therapies, especially chemotherapy, on the overall survival (OS) of patients with castration-resistant prostate cancer (CRPC) who were receiving [177Lu]Lu-PSMA-617 therapy. In this study, 11 clinics combined their patients’ data to provide a large number of patients for statistical analysis with high power.
This retrospective study was approved by the Ethical Committee of the Medical University of Innsbruck.
Page 1 of 2